OTC : AVCNF

Avicanna Inc.

$0.1 USD

$0.0 (4.17%)

Volume
20K
Average Volume
91.6K
Market Capitalization
$12.58M
P/E Ratio
-4.41
Dividend Yield
0.00%
Price Target
Year High
$0.24
Year Low
$0.07
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.96
Company Overview

OTC

Aras Azadian Mba

Drug Manufacturers - Specialty & Generic

Healthcare

AVCNF

112

CA

USD

https://www.avicanna.com

+1 647 243 5283

05368K100

N/A

Liquidity Metrics

0.00

0.96

0.49

0.04

0.00

Sales & Valuation

$25.46M

0.66

4.15

-7.55

-0.02

Profitability

-$0.0248

-$2.84M

-13.90%

-12.09%

-116.09%

-16.26%

P/E Metrics

-4.41

0.09

0.09

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Financial Health Scores

-4.96

2/9

-$322.1K

$22.14M

$9.31M

-$3.35M

Key Metrics (TTM)

$16.61M

0.64

-6.31

0.96

-116.09%

-25.02%

-22.34%

-13.24%

-72 days

Company Executives
Name Title
Karolina Urban Executive Vice President of Scientific & Medical Affairs
Aras Azadian Mba Co-Founder, Chief Executive Officer & Director
Stephen Kim Chief Legal Officer, General Counsel & Corporate Secretary
Nick Hilborn Chief Financial Officer
Carlos Enrique Maldonado Muete SVP of Clinical Development
Ivana Maric Executive Vice President of Marketing
Poll Results

No votes yet today — be the first to share your view!

About Avicanna Inc. (OTC:AVCNF) Stock

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-s ... pectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

2026-07-16 07:30:00

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

2026-06-30 17:30:00

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

2026-06-15 08:30:00

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.

Avicanna Announces Closing of Non-Brokered Private Placement

2026-06-12 17:30:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 4,000,014 ‎‎units of the Company (“Units”) at a price of $0.15 per Unit for aggregate gross proceeds of $600,002.1 (“Offering”).

Avicanna Reports Q1 2026 Financial Statements

2026-05-14 07:30:00

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

Avicanna Inc. (AVCN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

2026-05-10 06:41:13

Avicanna Inc. (AVCN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Avicanna Announces Results of Annual General and Special Meeting

2026-05-08 07:30:00

TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management's nominees listed in the Company's management information circular dated April 2, 2026 (“Circular”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“Meeting”).

Avicanna Announces Change in Board of Directors

2026-05-01 20:46:30

TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026, has tendered her resignation as a member of the board of directors effective Friday May 1, 2026 ahead of the annual general and special meeting of shareholders.

Frequently Asked Questions

What is the current Avicanna Inc. (AVCNF) stock price?

Avicanna Inc.(OTC:AVCNF) stock price is $0.1 in the last trading session. During the trading session, AVCNF stock reached the peak price of $0.236 while $0.068 was the lowest point it dropped to. The percentage change in AVCNF stock occurred in the recent session was 4.17% while the dollar amount for the price change in AVCNF stock was $0.0.

AVCNF's industry and sector of operation?

The OTC listed AVCNF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AVCNF?

Karolina Urban | Executive Vice President of Scientific & Medical Affairs
Aras Azadian Mba | Co-Founder, Chief Executive Officer & Director
Stephen Kim | Chief Legal Officer, General Counsel & Corporate Secretary
Nick Hilborn | Chief Financial Officer
Carlos Enrique Maldonado Muete | SVP of Clinical Development

How many employees does AVCNF have?

Number of AVCNF employees currently stands at 112. AVCNF operates from 480 University Avenue, Toronto, ON M5G 1V2, CA.

Link for AVCNF official website?

Official Website of AVCNF is: https://www.avicanna.com

How do I contact AVCNF?

AVCNF could be contacted at phone #+1 647 243 5283 and can also be accessed through its website. AVCNF operates from 480 University Avenue, Toronto, ON M5G 1V2, CA.

How many shares of AVCNF are traded daily?

The average number of AVCNF shares traded daily for last 3 months was 91.6K.

What is the market cap of AVCNF currently?

The market value of AVCNF currently stands at $12.58M with its latest stock price at $0.1